Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most
common cause of mortality and morbidity. The CRC incidence in adolescents, young adults …

How can we treat cancer more effectively? Traditionally, tumours from the same anatomical
site are treated as one tumour entity. This concept has been challenged by recent …

Background The anti-EGFR monoclonal antibodies panitumumab and cetuximab are
effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic …

Abstract PI3K/AKT signaling leads to reduced apoptosis, stimulates cell growth and
increases proliferation. Under normal conditions, PI3K/AKT activation is tightly controlled …

Worldwide, colorectal cancer (CRC) remains a major cancer type and leading cause of
death. Unfortunately, current medical treatments are not sufficient due to lack of effective …

There are multiple applications of molecular tests in clinical oncology. Mutation analysis is
now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of …

Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a tumor
suppressor gene located at chromosome 10q23. 31, encoding for a 403-amino acid protein …

Background: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma.
The increased understanding of this pathway led to the identification of new promising drugs …

Purpose: KRAS mutations are predictive of nonresponse to anti-EGFR therapies in
metastatic colorectal cancer (mCRC). However, only 50% of nonmutated patients benefit …

Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in
many cancers, including colorectal cancer. We investigated whether activation of YAP1 is …